FDA Confirmation Hearing Gives Update on Abortion Pill Study Under New Leadership

Dr. Heidi Overton, nominated by President Donald Trump to lead the Food and Drug Administration, appeared before a Senate committee on Thursday and shared an update on the long-awaited abortion pill study.

Overton told the Senate Committee on Health, Education, Labor and Pensions that if she is confirmed, the updates to the study would be on her desk immediately. She assured the committee of her commitment to oversee the study and provide transparency of the results.

The FDA is currently conducting a safety study on the chemical abortion drug mifepristone. The Biden administration formerly changed the risk evaluation and mitigation strategy, or REMS, and removed the in-person prescription requirement, allowing for unregulated use of the abortion pill.

Now pro-life lawmakers are attempting to remove the drug from the market entirely. This starts with the FDA conducting the safety study, which is expected to be completed by the end of the year.

“I’m disappointed that the FDA has removed so many guardrails from this dangerous drug, which carries the strongest black box warning,” said Sen. Jim Banks, R-Ind., at the hearing. “Can you tell us when that safety study will be completed, and will you commit to accelerating the safety study in the interest of women’s safety?”

“If I have the privilege of being confirmed, this will be something that would immediately be on my desk, as I understand the FDA has an update due to the court on Oct. 7 of the process that it is in, and it is a process update,” Overton answered.

“I’m not currently involved in the details of the study, but if I’m confirmed, I would immediately get briefed and be updated on the process and be able to give better answers on the estimated timelines of when that review will be completed,” she continued. “The commitment would be that that study has to be done in the most durable scientific way possible, and the results communicated transparently.”

Overton said her job would be to make sure the study is well designed, the analysis is “adjusted properly,” and the results are shared transparently.

“All Americans [should] have an opportunity to know what exactly is in those findings,” she concluded.

Overton was initially supported by pro-lifers. Upon Trump’s nomination, she was quickly endorsed by Americans United for Life CEO John Mize.

“Dr. Overton is the right candidate,” he said. “She has the scientific and medical background that will enable her to perform an objective analysis of the dangers chemical abortion poses to women. Americans United for Life supports Dr. Overton as the next commissioner of the FDA.”

Some Pro-Lifers Demand More

However, some pro-lifers say they want more from the nominee.

“Dr. Heidi Overton was disappointing, as she pretended that because the FDA has said ‘there is nothing to see here’ when it comes to chemical abortion pills, it wasn’t worth a clear statement,” Students for Life of America President Kristan Hawkins wrote on X following the hearing.

“The issue is not just reckless distribution of these pills to sex abusers and the complete lack of REMS [risk evaluation and mitigation strategy], but the body count of babies, mothers, and even potentially endangered species must be addressed. We know of huge health risks and environmental concerns the reckless deregulation of mifepristone brought on the market through the FDA, even with their original Black Box Medical Warning Label,” Hawkins wrote.

“Her responses today illustrate why we just filed our notice of intent to sue the FDA. If she is confirmed, we expect our notice to be at the top of the pile on her new desk,” she concluded.

More from this network:
Domains for Sale · GOTPeople.org · TheDSAPlatform · The Truth About Socialism

Donate to GOTPeople.org